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Cost-effectiveness analysis of additional docetaxel for metastatic hormone-sensitive prostate cancer treated
with androgen-deprivation therapy from a Chinese perspective
The E3805 (CHAARTED) study found that docetaxel combined with androgen-deprivation therapy (ADT)
significantly improved overall survival of patients with metastatic hormone-sensitive prostate cancer. This
study aims to determine whether docetaxel combined with ADT is a cost-effective strategy for advanced
prostate cancer in China. According to the E3805 study, two groups (docetaxel + ADT and ADT alone) and
three health states [progression-free survival (PFS), progressive disease (PD) and death] were analysed in a
Markov model. All medical costs were calculated from the Chinese societal perspective. Quality-adjusted life
year (QALY) and incremental cost-effectiveness ratios (ICERs) were applied as the primary outcome. Overall,
the addition of docetaxel was estimated to increase the cost by $12 816.93, with a gain of 0.48 QALY.
Additionally, for patients with high-volume disease, the increased cost and effectiveness were $14 627.75 and
0.69 QALYs in docetaxel + ADT group versus the ADT alone group, and the ICER was $21 199.63 per QALY.
These ICERs are far more than the commonly accepted willingness-to-pay (WTP) threshold of $20 301 per
QALY in China. In spite of longer survival time, docetaxel combined with ADT is not a recommended cost-
effective treatment for metastatic hormone-sensitive prostate cancer in the Chinese setting.
Keywords: cost-effectiveness, prostate cancer, docetaxel, androgen-deprivation therapy.
INTRODUCTION
Prostate cancer is the second most frequently diagnosed
cancer in men, and ranks fifth in estimated deaths
worldwide (Siegel et al. 2015). In China, the incidence is
increasing, reflecting risk factors including an increased
consumption of animal fats, obesity and physical inactiv-
ity, which are associated with economic development
(Potosky et al. 1995; Center et al. 2012; Siegel et al.
2015). Although death rates for prostate cancer have been
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decreasing in the majority of developed countries (a result
of early detection and improved treatment), mortality
rates are rising in some Asian and Central and Eastern
European countries, including China, with an estimated
5-year survival rate at 54% (Potosky et al. 1995; Center
et al. 2012; Hongmei et al. 2015; Siegel et al. 2015).
The majority of prostate cancer-related deaths result
from metastatic spread of prostate cancer cells from the
primary tumour to contiguous and distal sites (Maluf
et al. 2012). Targeting the androgen receptor axis has been
long known as an effective strategy in metastatic prostate
adenocarcinoma, and androgen-deprivation therapy (ADT)
has been the mainstay of treatment for metastatic prostate
cancer since the 1980s (Jr et al. 1987). Surgical excision of
the testes or the use of drugs to interrupt signalling
between the pituitary gland and the testes are curative
options of ADT (Nishiyama 2008). However, a recent
study demonstrated limited improvement in overall sur-
vival (OS) for patients diagnosed with metastatic hor-
mone-sensitive prostate cancer treated with ADT (Wu
et al. 2014). Subsequently, the TAX 327 study showed
that the OS of patients with hormone-resistant prostate
cancer treated with docetaxel plus prednisone was statisti-
cally longer than those treated with mitoxantrone and
prednisone (19.2 versus 16.3 months; P = 0.004; Tannock
et al. 2004). Hence, docetaxel was approved by the US
Food and Drug Administration for castration-resistant
prostate cancer. However, whether docetaxel can improve
outcomes for metastatic hormone-sensitive patients was
still unknown.
Most recently, the E3805 (CHAARTED) trial, which
compared ADT alone and ADT plus docetaxel for meta-
static hormone-sensitive prostate cancer, showed that 6
cycles of docetaxel at the beginning of ADT for metastatic
prostate cancer resulted in significantly longer OS than
that with ADT alone (57.6 months versus 44.0 months;
P < 0.001). In the subgroup with high-volume disease
(presence of visceral metastases or ≥4 bone lesions with ≥1
beyond the vertebral bodies and pelvis), the benefit was
even greater, with a median 17.0 months longer OS in the
combination group than in the ADT alone group [hazard
ratio (HR) = 0.60; P < 0.001] (Sweeney et al. 2015).
Despite the obvious benefit in OS, ADT plus docetaxel,
compared to ADT, has been found to increase the inci-
dence of various side effects, including grade 3 or 4 neu-
tropenia, anaemia, thrombocytopenia and febrile
neutropenia (Sweeney et al. 2015). In addition to adverse
drug reactions, the use of docetaxel may cause an addi-
tional monetary burden for patients, especially those in
developing countries, such as China. Thus, it is critical to
identify whether docetaxel is a cost-effective option for
patients with metastatic hormone-sensitive prostate can-
cer. The aim of this study was to conduct a cost-effective-
ness analysis using a Markov decision model to compare
ADT and ADT plus docetaxel for metastatic hormone-
sensitive prostate cancer patients based on the E3805 trial
from the Chinese societal perspective.
MATERIALS AND METHODS
Patients
The patient data analysed in the current study was origi-
nally from the E3805 trial, which found the advantage of
ADT and docetaxel concomitant therapy compared with
ADT alone in the treatment of metastatic, hormone-sensi-
tive prostate cancer. In short, 790 qualified patients with
histologically or clinically confirmed prostate cancer, and
radiological evidence of metastatic disease were included
in the research. High-volume metastasis was defined as
the presence of visceral metastases or ≥4 bone lesions with
≥1 beyond the vertebral bodies and pelvis (Sweeney et al.
2015). Among the patients, 397 were in the ADT plus doc-
etaxel group and 393 in the ADT alone group. The median
age was 63, and their Eastern Cooperative Oncology
Group performance status ranged from 0 to 2.
The treatments
The clinical trial has been described elsewhere (Sweeney
et al. 2015). In brief, all patients were required to take cal-
cium carbonate at least 500 mg per day and vitamin D no
less than 400 IU every day. Every patient received ADT
according to the protocol (Sweeney et al. 2015). For ADT
plus docetaxel group, docetaxel was given at a dose of
75 mg/m2 of body surface area every 21 days for maxi-
mum of 6 cycles; a dose of 8 mg oral dexamethasone was
taken 12, 3 and 1 h prior to docetaxel infusion. The
response evaluation was conducted, and grade 3 or higher
toxic effects were captured (Sweeney et al. 2015). Treat-
ments of the second-line included cabazitaxel, mitox-
antrone, abiraterone, antiandrogen (flutamide) and
docetaxel, as demonstrated in the E3805 study (Sweeney
et al. 2015).
Clinical outcomes
For all participants in the study cohort, the median OS
was 57.6 months in the combination group compared
with 44.0 months in the ADT group [HR = 0.61; 95% con-
fidence interval (CI), 0.47–0.80; P < 0.001]. Notably, the
survival benefit was more significant in the high-volume
disease patients, which was 49.2 months in the combina-
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tion group and 32.2 months in the ADT alone group
(HR = 0.60; 95% CI, 0.45–0.81; P < 0.001). Among the
combination therapy patients, the grade 3 or 4 febrile neu-
tropenia rate was 6.2%, the grade 3 or 4 infection with
neutropenia rate was 2.3%, and the grade 3 sensory neu-
ropathy and grade 3 motor neuropathy were 0.5% (Swee-
ney et al. 2015).
Overall concept of the Markov model
To evaluate the economic consequences and therapeutic
efficacy associated with each testing item and treatment
strategy, a Markov decision model was built using Treeage
software (Treeage, Williamstown, MA, USA). The time
horizon was 10 years, which was nearly lifelong and the
transition cycle length was 1 year. The transition diagram
among model states is presented in Figure 1. The costs
were calculated from the Chinese societal perspective,
and survival was reported in quality-adjusted life years
(QALYs). The incremental cost-effectiveness ratios
(ICERs) were calculated as the difference in costs divided
by the difference in effectiveness between a given strategy
and the next most cost-effective alternative.
The strategies and Markov model structure
Two groups were analysed: patients treated with docetaxel
and ADT combination therapy and patients treated with
ADT alone. Three health states were analysed: progression-
free survival (PFS), progressive disease (PD) and death (Fig. 1).
A patient was assumed to enter the model at the PFS state
and received either docetaxel and ADT combination therapy
or ADT alone as the first-line treatments until one of the fol-
lowing events occurred: progression of disease (PD stage),
intolerable toxicities or death. The transition probabilities of
health states were estimated based on an equation used pre-
viously: Pð1monthÞ ¼ ½1 ð0:5Þð1=median time to eventÞ,
which was derived from the equations below: P = 1-eR and
R = ln [0.5]/(time to event/number of treatment cycles)
(Purmonen et al. 2008; Petrou & Talias 2014).
Figure 1. Markov model for metastatic prostate cancer patients based on the trial of E3805. According to the E3805 profile, two groups
were analysed: group 1, patients with metastatic prostate cancer treated with ADT + docetaxel; group 2, patients with metastatic pros-
tate cancer treated with ADT. A Markov model comprising three health states (PFS, PD and death) was built. ADT, androgen-depriva-
tion therapy; PD, progression disease; PFS, progression-free survival.
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Based on the equation, monthly transition probability
from PFS state to PFS state (pPFS-PFS), from the PFS to PD
(pPFS-PD), from PFS to death (pPFS-death), from PD to PD
(pPD-PD) and from PD to death (pPD-death) are described
in Table 1.
The utilities
We calculated the effectiveness data in each group based
on the health-related quality of life. Preference-based
health states utility scores were derived from previously
published studies and the values were set at 0.8 for PFS
state, 0.6 for PD state and 0 for death respectively (Heijns-
dijk et al. 2015). Since the patients’ performance status of
the treatments in two groups was very similar, the same
utility values were applied in the model.
Measurement of costs
Costs were calculated from the Chinese societal perspec-
tive. Costs for the first-line therapies as well as second-
line treatments were included in the analysis. Both direct
costs and indirect costs were taken into account. Direct
costs were associated with costs of drugs, hospitalisation
and necessary tests for efficacy/safety evaluation during
the treatments. Indirect costs included costs related to
grade 3–4 adverse events (AEs), and calcium carbonate and
vitamin D costs. Detailed data on the grade 3–4 AEs were
derived from the records of E3805 study. All costs were
converted into US dollars, with an exchange rate of
$1 = ￥6.39 (26 August 2015).
Cost-effectiveness analysis
Based on the data collected above, a cohort of 100 000
patients was simulated randomly, using the Monte Carlo
simulation to imitate the process of metastatic prostate
cancer. The model was run until all the hypothetical
patients died. Costs and effectiveness were discounted at
3% per year.
Subgroup analyses
We also conducted subgroup analyses based on the extent
of metastases. The efficacy data of patients with high/low-
volume disease were derived from the Kaplan–Meier
survival curves of patients in the subgroups. The cost-
effectiveness data of addition of docetaxel to ADT com-
pared with ADT alone in the subgroups were measured
according to the methods mentioned above.
Sensitivity analysis
One-way sensitivity analysis was performed to examine
the impact of essential factors on the model. The ranges of
the factors analysed were calculated by increasing or
decreasing them by 20% (Elbasha & Messonnier 2004).
According to World Health Organization guidelines for
cost-effective analysis, the willingness-to-pay (WTP) was
set to $20 301.00 per year, which is 39 GDP per capita of
China (Murray et al. 2000; Eichler et al. 2004). In addi-
tion, probabilistic sensitivity analysis was performed by
conducting a second-order Monte Carlo simulation to esti-
mate different optimal strategies with varied WTP thresh-
olds (Price & Briggs 2002).
RESULTS
Effectiveness
According to the results of E3805 study, the additional
docetaxel has significantly improved the clinical outcome
combined with ADT, especially for patients with high-
volume disease (Sweeney et al. 2015). Hence, the benefi-
cial outcomes contributed to a gain of 0.48 QALYs for the
docetaxel and ADT combination group (2.74 QALYs ver-
sus 2.26 QALYs). For the patients with high-volume dis-
ease, the effectiveness for docetaxel and ADT
combination group was 2.34 QALYs compared to 1.65
QALYs in the ADT alone group, which was 0.69 QALYs
longer. The details are listed in Table 2.
Costs
Treatment associated costs were defined as per month per
patient in one transition cycle from the Chinese societal
perspective, which was calculated according to the treat-
ment duration and total number of treatment cycles
Table 1. Transition probabilities used in the analysis
Value Lower limit Higher limit
ADT+D group
pPFS-PFS-1 0.967 0.774 1.000
pPFS-PD-1 0.021 0.017 0.025
pPFS-death-1 0.012 0.010 0.014
pPD-PD-1 0.972 0.778 1.000
pPD-death-1 0.028 0.022 0.034
ADT group
pPFS-PFS-2 0.95 0.760 1.000
pPFS-PD-2 0.034 0.027 0.041
pPFS-death-2 0.016 0.013 0.019
pPD-PD-2 0.972 0.778 1.000
pPD-death-2 0.028 0.022 0.034
PFS, progression-free survival; PD, progressive disease; ADT,
androgen-deprivation therapy; D, docetaxel.
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collected from the E3805 study, as listed in Table 2. Cost
for PFS state was far more than the PD state in both
groups. In detail, costs for PFS state, including regimen
fees (docetaxel, ADT, dexamethasone), costs of hospitali-
sation, necessary tests for efficacy/safety evaluation
during the treatments, grade 3–4 AEs-related costs, and
calcium carbonate and vitamin D costs, were $24 035.64
in the combined group and $9916.45 in the ADT alone
group; costs for PD state were $3051.13 in the combined
group and $4353.40 in the ADT alone group. In total, the
incremental cost was $12 816.93 in the combined group
compared with the ADT alone group ($27 086.78 versus
$14 269.85). Information regarding grade 3–4 AEs analysed
in the model are illustrated in Table 3.
Cost-effectiveness analysis
Evidently, no strategy clearly dominated the others,
which means that although docetaxel and ADT combi-
nation group was more effective compared to the ADT
alone group, the strategy was also more costly. That is,
the docetaxel and ADT combination group spent
$9885.69 per QALY compared with $6314.09 per QALY
for the ADT alone group. In the base-case analysis, the
ICER of docetaxel and ADT combination group com-
pared with the ADT alone group was $ 26 701.94 per
QALY, which was far more than the commonly
accepted WTP threshold ($20 301 per QALY in China)
(Fig. 2A). Generally, incremental cost-effectiveness scat-
terplots of ADT alone group were distributed above the
WTP (Fig. 3A).
For the subgroup of patients with high-volume disease,
the docetaxel and ADT combination group spent
$11 077.37 per QALY compared with $6844.42 per QALY
for the ADT alone group, and the ICER of the docetaxel
and ADT combination group compared with the ADT
alone group was $21 199.63 per QALY, which also
exceeded the WTP threshold (Fig. 2B). The incremental
cost-effectiveness scatterplots of patients with high-
volume disease were almost the same as the overall anal-
ysed population (Fig. 3B).
Sensitivity analysis
A one-way sensitivity analysis was applied, which pro-
vides an insight into the responsiveness of the model
results to the changes of parameters analysed in the study.
The robustness of the results was also tested. The vari-
ables in the sensitivity analysis varied at a range of 20%.
Results of the sensitivity analysis depicted that most
factors showed influences on the model results including
the costs of docetaxel, ADT, vitamin D and calcium car-
bonate. Changes in costs for docetaxel had the greatest
impact on the results of the analysis. As the value of doc-
etaxel changed from $220.54 to $330.81, ICER (docetaxel
and ADT combination group versus the ADT alone group)
ranged significantly from $23 830.53 to $30 206.81 per
QALY, and the cost/effect changed from $9340.39 to
$10 443.81 per QALY for the docetaxel plus ADT group.
Additionally, the cost-effectiveness analysis was also sen-
sitive to the test costs of the two groups and hospital fees
(Fig. 4).
Table 2. Results of the cost-effectiveness analysis
ADT + D ADT
Cost ($)
Costs for PFS per month
Docetaxel 275.67 –
Dexamethasone 0.098 –
Hospital 4.54 0
ADT 310.92 310.92
Test 214.73 152.39
AE 0.40
Calcium carbonate 4.18 4.18
Vitamin D 66.63 66.63
Total 877.18 534.12
Costs for PD per month 172.90 216.54
Costs for PFS state 24 035.64 9916.45
Costs for PD state 3051.13 4353.40
Total costs 27 086.78 14 269.85
Incremental costs 12 816.93
Effectiveness (QALYs)
effectiveness for PFS state
1.85 1.26
Effectiveness for PD state 0.88 1.01
Total effectiveness 2.74 2.26
Incremental effectiveness 0.48
Cost/effectiveness 9885.69 6314.09
Incremental cost/effectiveness 26 701.94
AE, adverse event; PFS, progression-free survival; PD, progres-
sive disease; QALY, quality-adjusted life year; ADT, androgen-
deprivation therapy; D, docetaxel.
Table 3. Adverse events-related costs of metastatic prostate
cancer patients treated with docetaxel and ADT combination
Items
Grade
3 (N)
Grade
4 (N)
Cost for
grade 3 ($)
Cost for
grade 4 ($)
Allergic reaction 7 1 3.78 1.62
Fatigue 16 0 0.00 0.00
Diarrhoea 4 0 13.64 0.00
Stomatitis 2 0 31.28 0.00
Neuropathy, motor 2 0 0.00 0.00
Neuropathy, sensory 2 0 0.00 0.00
Thromboembolism 1 2 10.54 63.25
Sudden death 0 0 0.00 0.00
Anaemia 4 1 56.66 42.49
Thrombocytopenia 0 1 0.00 548.49
Neutropenia 12 35 433.35 3791.84
Febrile neutropenia 15 9 541.69 975.04
Infection with
neutropenia
5 4 180.56 433.35
ADT, androgen-deprivation therapy.
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Probabilistic sensitivity analysis (acceptability frontier)
A probabilistic sensitivity analysis was performed to take
into account the uncertainty surrounding estimated
parameters. In the cost-effectiveness acceptability curve,
the probability of being cost-effective is represented as a
function of increasing levels of WTP. With the respect to
WTP, as the value varied from $0 to $40 602.00, the
acceptable proportion of the ADT alone group was
decreased, whereas the docetaxel and ADT combination
group was increased (Fig. 5).
DISCUSSION
The OS of patients with metastatic castration-resistant
prostate cancer has achieved much improvement with the
development of next-generation cytotoxic chemotherapy,
novel hormonal therapies such as enzalutamide and abi-
raterone acetate, immunotherapy (sipuleucel-T, ipili-
mumab) and radiopharmaceutical agents radium-223
(Mehta & Armstrong 2016). However, few studies have
investigated how to improve the clinical outcomes in men
with metastatic hormone-sensitive disease. The European
Figure 2. Cost-effectiveness pictured with two groups. Two groups were analysed: group 1, patients with metastatic prostate cancer
treated with ADT + D; group 2, patients with metastatic prostate cancer treated with ADT. ADT, androgen-deprivation therapy; D,
docetaxel; QALY, quality-adjusted life years. (A) Cost-effectiveness analysis of whole patients’ population. (B) Cost-effectiveness analy-
sis of patients with high-volume disease.
Figure 3. Incremental cost-effectiveness scatterplot of two groups. Two groups were analysed: group 1, patients with metastatic pros-
tate cancer treated with ADT + D; group 2, patients with metastatic prostate cancer treated with ADT. Cost-effectiveness distribution
of two groups. ADT, androgen-deprivation therapy; D, docetaxel. (A) Incremental cost-effectiveness scatterplot of whole patients. (B)
Incremental cost-effectiveness scatterplot of patients with high-volume disease.
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GETUG-AFU-15 study was the first to assess the use of
docetaxel in men with metastatic hormone-sensitive pros-
tate cancer (Gwenaelle et al. 2013). Despite the improve-
ment in PFS, the study found no statistically significant
difference in the primary end point of OS between the two
groups (HR = 0.9; P = 0.44). In addition, there was no sig-
nificant difference in OS for either the high- or low-
volume disease subgroups.
More recently, however, the E3805 study showed a sig-
nificantly improved OS in metastatic hormone-sensitive
prostate cancer patients treated with docetaxel plus ADT
compared with ADT alone, especially in those with
high-volume disease. These finding led to the update of
the National Comprehensive Cancer Network (NCCN)
clinical practice guidelines on the treatment of high-
volume, ADT-na€ıve, metastatic hormone-sensitive pros-
tate cancer. With the additional chemotherapy, the medi-
cal burden will no doubt be increased dramatically, and it
is of great importance to make a preferred treatment rec-
ommendation for patients with metastatic hormone-sen-
sitive prostate cancer, especially in a resource-limited
country such as China.
In this cost-effectiveness study, we found that
chemotherapy with 6 cycles of docetaxel with concurrent
ADT is not an affordable choice for patients with meta-
static hormone-sensitive prostate cancer at the Chinese
societal perspective. Using a decision analytic model, we
estimated that the docetaxel and ADT combination group
spent $9885.69 per QALY compared with $6314.09 per
QALY for the ADT alone group. Docetaxel improves the
survival of the patients by 0.48 QALY at additional cost
of $12 816.93. For patients with high-volume disease, the
increased cost and effectiveness were $14 627.75 and 0.69
QALYs in the docetaxel plus ADT group versus the ADT
alone group respectively, and the ICER was $21 199.63
per QALY. These ICERs were higher than the commonly
accepted WTP threshold of $20 301 per QALY in China.
Thus, the results indicate that ADT plus docetaxel is not
a cost-effective regimen for metastatic hormone-sensitive
prostate cancer in China, even for patients with high-
volume disease. Of note, docetaxel and growth factor
generics have the advantage of lower price, which was the
most sensitive factor affecting the results of the current
analysis model. However, currently no survival or AE
results have been published of docetaxel generics in
patients with metastatic hormone-sensitive prostate can-
cer. If patients’ effects and tolerance to the generics is the
same as the originator, the lower price may lead to a more
cost-effective treatment strategy. Furthermore, we rea-
lised that chemotherapy with docetaxel made the cost
much higher than ADT alone, not only because of the
expense of the chemotherapy agent itself but also the fees
related to hospitalisation, AEs and necessary tests for
safety evaluation during the treatments. Notably, there
was one treatment-related death among patients receiving
Figure 4. Tornado Diagram of metastatic prostate cancer. Tor-
nado diagram summarised the results of one-way sensitivity
analysis to identify model variables associated with the two
strategies in the treatment of metastatic prostate cancer. The
influential factors were listed descending with the variation of
value. ADT, androgen-deprivation therapy; Test1, test costs for
ADT plus docetaxel group; Test2, test costs for ADT along
group; Hospital, hospital fees.
Figure 5. Probabilistic sensitivity analysis (acceptability fron-
tier). The cost-effectiveness acceptability frontier shows the
probability of strategies being cost-effective in two strategies.
For different willingness-to-pay thresholds, the proportion for
ADT was decreased, while the ADT + D was increased. ADT,
androgen-deprivation therapy; D, docetaxel.
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ADT plus docetaxel, although the E3805 study reported
few grade 3–4 haematological AEs (Sweeney et al. 2015).
There is a possibility that AEs were underestimated as
blood counts were not monitored routinely between
chemotherapy cycles (Fizazi et al. 2015). It has been
reported that the toxicity of docetaxel is mediated, in part,
by hormonal mechanisms (Fitzpatrick & Ronald 2014).
Hence, cost related with AEs might be underestimated.
This cost-effectiveness analysis, to the best of our
knowledge, is the first study to investigate whether
chemotherapy combined with ADT is a cost-effective
option for metastatic hormone-sensitive prostate cancer.
Several cost-effective analyses have been done on similar
patient populations on various ADT treatments. First,
combined androgen blockade therapy with bicalutamide
was confirmed to be cost-effective when compared with
LH-RH monotherapy in stage D2 prostate cancer (Penson
et al. 2005). Then, using modelling with meta-analysis of
comparative survival data, another study concluded that
leuprorelin 22.5 mg was a more cost-effective treatment
than leuprorelin 11.25 mg, triptorelin 11.25 mg, buserelin
9.9 mg and goserelin 10.8 mg (Iannazzo et al. 2011). Later,
researchers from the UK showed that degarelix is unlikely
to be cost-effective compared to triptorelin plus short-
term antiandrogen (Lu et al. 2012). All these cost-effec-
tiveness analyses assessed the value of different ADT for
patients with metastatic hormone-sensitive prostate can-
cer, but cannot supply decision-making information on
chemotherapy.
However, this cost-effective analysis has several
limitations. First, the clinical information was from the
American study E3805, while cost data were collected
from a single Chinese hospital. Furthermore, we con-
ducted a cost-effectiveness acceptability frontier analysis,
which showed the probability of strategies being cost-
effective. For decision-makers in other countries with
different WTP thresholds, different strategies might be
optimal. Second, no data of quality of life were available
from the E3805 study so utilities for the state of PFS and
PD were referenced with previous published research,
which may influence the calculation of QALYs. Finally,
our analysis did not take into account the costs of AEs
caused by the second-line therapy because no informa-
tion was available.
In summary, our study showed that despite a longer sur-
vival time, 6 cycles of docetaxel combined with ADT is
not a preferred cost-effective treatment for metastatic hor-
mone-sensitive prostate cancer in the Chinese setting,
even for patients with high-volume disease. A reduction
in the price of docetaxel and further research are needed to
improve the cost-effectiveness for metastatic hormone-
sensitive prostate cancer; further studies might include
distinguishing patients with de novo metastases at diag-
nosis from those who developed metastases following
treatment of localised disease, considering combination of
ADT with novel treatment strategies, and investigating
concurrent or sequential ADT and chemotherapy. Never-
theless, this analysis provides evidence from an economic
perspective regarding the addition of chemotherapy to
hormone therapy in the treatment of prostate cancer.
The conclusions will be helpful for the decision-making
of physicians, patients and healthcare management
structures.
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